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and miR-125b). For the first time, we suggest that miR-
150 might be potential negative regulator for two critical 
cell cycle control genes, RAD54L and CCNA2, whereas 
miR-125b potentially target RAS and CysLT signaling pro-
teins, namely RASGRF2 and CYSLTR2, respectively. This 
study has enhanced our understanding on the pathobiology 
of MM and opens up new avenues for future research in 
myelomagenesis.
Keywords Multiple myeloma · MicroRNA · Microarray · 
MiRNA-mRNA integrative analysis · MiR-150 · MiR-125b
Introduction
Multiple myeloma (MM) is a malignancy of B lympho-
cytes, characterised by clonal expansion of malignant 
plasma cells in the bone marrow and over-production 
of intact monoclonal immunoglobulin of a single type 
(M-protein) (Eslick and Talaulikar 2013). It is the second 
most common haematological malignancy in the world (De 
Mel et al. 2014). Despite central role of genomic changes, 
epigenetic changes such as DNA methylations, histone 
modifications and non-coding RNAs arise as crucial factors 
in the transformation and progression of this malignancy.
microRNAs (miRNAs) are a class of ~20–25 nucleo-
tides small non-coding, double-stranded RNA molecules. 
The mature miRNAs bind to their targets (usually at the 3′ 
untranslated region) and regulate the target gene expres-
sion by translation repression or mRNA degradation (Bi 
and Chng 2014). miRNAs are important in regulating the 
gene expression essential for normal cellular functions, 
aberrant expression of miRNAs has been implicated in 
many human diseases and phenotypic variations includ-
ing MM (Lorio and Crose 2012; Bi and Chng 2014). In 
Abstract Epigenetic changes have emerged as key causes 
in the development and progression of multiple myeloma 
(MM). In this study, global microRNA (miRNA) expres-
sion profiling were performed for 27 MM (19 specimens 
and 8 cell lines) and 3 normal controls by microarray. 
miRNA-targets were identified by integrating the miRNA 
expression profiles with mRNA expression profiles of the 
matched samples (unpublished data). Two miRNAs were 
selected for verification by RT-qPCR (miR-150-5p and 
miR-4430). A total of 1791 and 8 miRNAs were over-
expressed and under-expressed, respectively in MM com-
pared to the controls (fold change ≥2.0; p < 0.05). The 
miRNA-mRNA integrative analysis revealed inverse cor-
relation between 5 putative target genes (RAD54L, CCNA2, 
CYSLTR2, RASGRF2 and HKDC1) and 15 miRNAs 
(p < 0.05). Most of the differentially expressed miRNAs 
are involved in survival, proliferation, migration, inva-
sion and drug resistance in MM. Some have never been 
described in association with MM (miR-33a, miR-9 and 
miR-211). Interestingly, our results revealed 2 miRNAs, 
which are closely related to B cell differentiation (miR-150 
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cancer, miRNAs function as regulatory molecules that 
can act as either an oncomiR or a tumour suppressor 
(Bi and Chng 2014). Their abnormal expression causes 
tumour formation by disrupting mechanisms that control-
ling apoptosis, angiogenesis, cell proliferation, invasion, 
and other critical signaling pathways (Dimopoulos et al. 
2014).
miRNA expression profiles have been shown to be a 
powerful tool in the identification of novel biomarkers for 
diagnosis, prognosis and treatment of MM. To date, the 
number of miRNA studies in MM is still limited and insuf-
ficient to delineate the actual molecular events underly-
ing the pathogenesis of MM. In this study, global miRNA 
expression profiling was performed to identify potential 
miRNAs in the molecular pathogenesis of MM. Moreo-
ver, miRNA-targets were also examined by integrating 
the miRNA expression profiles with previously performed 
mRNA expression profiles of the matched samples (unpub-
lished data) by databases prediction and inverse correlation 
analysis. This study has enhanced our understanding on the 




Bone marrow aspirates or blood were collected from 
patients and healthy donors. Nineteen MM samples (MM1-
MM19) and 3 healthy controls were recruited in this study 
(N1, N2 and N3). The age of these patients ranged between 
28 and 74 years with a mean and median age of 57 and 
61, respectively. Seventeen out of 19 patients were newly 
diagnosed MM cases while the remaining 2 were relapsed 
cases. Samples for new cases were collected from the 
patients before treatment. Only patients with plasma cell 
infiltration >10% were included in this study.
Cell lines
Eight myeloma cell lines were used in this study. The 
RPMI-8226, U-266, MM.1S, and IM-9 MM cells were pur-
chased from American Type Culture Collection (ATCC, 
USA). Myeloma cell lines KMS-28-BM, KMS-20, KMS-
12-BM, and KMS-21-BM were obtained from Japanese 
Collection of Research Bioresources (JCRB) cell bank. 
Cells were cultured with RPMI1640 medium (ATCC) sup-
plemented with 10–15% fetal bovine serum (Lonza) in an 
incubator at 37 °C with humidified 5%  CO2. Cells were 
passaged every 3–4 days.
Total RNA extraction
Total RNAs were extracted from samples by using Qia-
gen RNeasy mini kit following manufacturer’s protocol. 
On-column DNase digestion was performed with the 
RNase-free DNase set to eliminate DNA contamination 
during RNA purification (Qiagen DNase I). The quality 
of total RNAs was assessed using RNA Nano Chip in 
Agilent’s 2100 Bioanalyser. The RNA integrity number 
(RIN) was >8.0 for all the samples included in this study. 
The purity of the RNA samples (A260 nm/ A280 nm) 
was within the range of 1.80–2.10 as measured by Nan-
oDrop ND-1000 UV–VIS spectrophotometer.
miRNA microarray assay
Briefly, 100 ng of total RNAs were labeled using Agilent 
miRNA Complete Labeling and Hyb Kit (Agilent Tech-
nologies) following manufacturer’s standard processing 
recommendations. Labeled RNAs were purified with 
MicroBioSpin 6 Column (Bio-Rad) to wash off unincor-
porated dyes. Purified labeled RNAs were dried in a vac-
uum concentrator at low heat. Pellet containing labeled 
miRNAs were resuspended in hybridisation cocktails 
and hybridised to SurePrint Human miRNA Microarray, 
release 19.0, 8 × 60 K (Agilent Technologies), which con-
tained probes for 2006 human miRNAs for 20 h at 55 °C 
with rotation. After incubation, microarray slide was 
washed and scanned with Agilent array scanner G2505C. 
Image was then analysed with Agilent Feature Extraction 
Software Version 10.7.3.1.
Arrays that passed QC criteria were proceeded for fur-
ther analysis. All the miRNA profiles were analysed by 
GeneSpring software version 13.0. All the miRNA data 
were thresholded to 1 and normalised to 75th percen-
tile. The entities were then filtered where at least 1 sam-
ple out of 30 samples have ‘present’ flag. Differentially 
expressed miRNAs in MM samples compared to the 
controls were determined by unpaired unequal variance 
t test. The Benjamin Hochberg false discovery rate mul-
tiple testing correction was applied. Entities were filtered 
at p-value cut-off 0.05 and fold change ≥2.0.
miRNA-target prediction and inverse correlation 
analysis
Identification of miRNA-targets was carried out by inte-
grating the miRNA expression profiles with previously 
performed mRNA expression profiles of the matched 
samples (unpublished data) using GeneSpring soft-
ware version 13.0. Putative target genes of differentially 
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expressed miRNAs were predicted by TargetScan at 
p < 0.05.
Quantitative reverse transcription-PCR (RT-qPCR)
Due to limitation of samples, RT-qPCR was performed to 
verify the expression of 2 differentially expressed miR-
NAs (miR-150-5p and miR-4430). The cDNA synthesis 
was carried out using miScript Reverse Transcription Kit 
(Qiagen) in a final volume of 20 µl containing 1× miScript 
HiSpec Buffer, 1× miScript Nucleic Mix, miScript Reverse 
Transcriptase Mix and 500  ng of RNA template accord-
ing to manufacturer’s instructions. miRNA specific prim-
ers, which were miR-150-5p (Cat. No.: HmiRQP0210) and 
miR-4430 (Cat. No.: HmiRQP2054) and internal control 
miRNA, RNU6 (Cat. No.: HmiRQP9001) were purchased 
from GeneCopoeia (USA). Quantification of miRNA 
expression levels were performed by using miScript SYBR 
Green PCR Kit (Qiagen) in Rotor-Gene Q 2-Plex (Qiagen, 
Hilden, Germany) according to manufacturer’s protocols.
The expression levels of the miRNAs were verified in 
20–25  MM samples depending on the availability of the 
samples. Two normal controls were used in each assay. All 
the RT-qPCR reactions were carried out in duplicates. The 
Ct values were normalised against internal controls and the 
fold difference of expression levels were calculated through 
relative quantification using 2−ΔΔCt method. The signifi-
cance level of MM and control groups was determined by 
student’s t-test.
Data availability
The miRNA microarray data generated in this study are 
available in the NCBI Gene Expression Omnibus (GEO) as 
series accession identifier GSE73048.
Results
Differentially expressed miRNAs in MM
A total of 1799 miRNAs were differentially expressed by 
≥2.0 fold change in MM samples compared to controls 
at p < 0.05. Out of 1799 miRNAs, 1791 and 8 miRNAs 
were over-expressed and under-expressed, respectively 
in MM. The miRNAs were more frequently up-regulated 
rather than down-regulated in MM, which is consist-
ent with microarray findings reported by Yusnita et  al. 
(2012), Zhou et  al. (2010) and Chi et  al. (2011). The 8 
under-expressed miRNAs were identified as miR-342-5p 
(−9.18), miR-151a-3p (−5.40), miR-361-3p (−4.30), 
miR-4298 (−3.88), miR-150-5p (−3.52), miR-199a-5p 
(−3.48), miR-374a-5p (−2.96) and miR-342-3p (−2.86). 
The top 100 significantly up-regulated miRNAs were 
listed in Online Resource 1. Only the top 100 dysregu-
lated miRNAs were discussed in this study.
Prediction of miRNA-targets in MM
Integrative analysis of significant differentially expressed 
miRNAs and mRNAs revealed 11 significantly expressed 
targeted genes (p < 0.05). They were PCOLCE2, ASPM, 
CKAP2L, CCNA2, SHCBP1, RAD54L, NUF22, CTN-
NAL1, HKDC1, CYSLTR2, and RASGRF2. When we 
associated the 11 targeted genes with the top 100 most 
significant dysregulated miRNAs, 5 putative target genes 
and 15 anti-correlated miRNAs were identified (Table 1). 
Theoretically, miRNAs are negative regulators for gene 
expression, the expression of a target mRNA is expected 
to be anti-correlated with miRNA expression (Lionetti 
et al. 2009). Therefore, only negative correlated miRNA-
mRNA targets were discussed in this study.
Verification of microarray results by RT-qPCR
Both miRNAs (miRNA-150-5p and miR-4430) were 
expressed at similar patterns as detected in microarray 
(p < 0.001) (Fig. 1).
Table 1  Significant negatively correlated miRNAs-mRNA expres-
sion networks identified in this study (p < 0.05)
Gene (fold change) miRNA (fold change)
RAD54L (17.00) miR-150-5p (−3.52)
CCNA2 (19.69) miR-150-5p (−3.52)
miR-374a-5p (−2.96)





















Previous studied showed that miRNA biogenesis in B cell 
malignancies are different with T cell malignancies in a 
way that the B-cell malignancies are more likely associated 
with a global increase in miRNA expression whereas T-cell 
malignancies with decrease in overall miRNA expression 
(Lawrie et al. 2008, 2009a, b; Zhang et al. 2009; Zhou et al. 
2010). This is also true in our case. The vast majority of 
differentially expressed miRNAs identified in this study 
were over-expressed in MM compared to the controls. 
Several aberrant miRNAs, which play critical roles in sur-
vival, proliferation, migration, invasion and drug resistance 
in MM were revealed. A more detail summary of aberrant 
miRNAs and their function, target and clinical relevance in 
oncogenesis are listed in Table 2.
Two important miRNAs involved in the IL6/STAT3 
pathway were over-expressed in MM compared to the con-
trols. They were miR-21 and miR-20a. The up-regulation 
of miR-21 is shown to facilitate the activation of IL6-
JAK-STAT pathway and STAT3, which is a major media-
tor of growth, proliferation and survival of myeloma cells 
conferred by bone marrow microenvironment. The IL6/
STAT3 activation enhances myeloma cell survival through 
the activation of anti-apoptotic genes, Mcl-1, Bcl-XL and 
c-Myc oncogene (Manier et al. 2012). It suggests that aber-
ration in miR-21 contributes in the early onset of MM (Chi 
et al. 2011). Apart from that, miR-20a is a member of the 
miR-17-92 cluster—one of the well characterised class of 
oncogenic miRNAs. Its over-expression in MM is shown 
to inactivate apoptotic genes, BIM and SOCS-1, a negative 
regulator of IL-6/STAT3 pathway (Pichiorri et al. 2008).
Deletion/ mutation of p53 gene play an important role 
in the oncogenesis of MM. The p53 gene is deleted in only 
5–10% of newly diagnosed MM cases but 40% of advanced 
MM (Gozzetti et  al. 2014). The incidence of deletion/ 
mutation of p53 increases as the stage of disease advances 
suggesting its critical role in disease progression (Gozzetti 
et al. 2014). Therefore, p53 abnormality is associated with 
poor prognosis and lower survival rate in MM (Drach et al. 
1998; Chng et al. 2007; Lodé et al. 2010). Apart from that, 
patient with p53 abnormality has decreased sensitivity to 
standard therapy (Teoh and Chng 2014). Under normal 
condition, p53 is expressed at low amount due to its con-
tinuous degradation by its negative regulator MDM2 (Her-
rero et al. 2016). The MDM2 is over-expressed in response 
to a variety of stress such as DNA damage, ribonucleotide 
depletion, nutritional starvation, hypoxia, and oncogene 
activation (Liu et al. 2014). Under stress condition, p53 is 
stabilised through interruption of the MDM2-p53 interac-
tion by mechanisms such as phosphorylation, acetylation, 
redistribution of protein complexes and modifications in 
the subcellular localisation, which resulted in p53 path-
way activation (Feng and Levine 2010; Vousden and Prives 
2009). Activation of p53 pathway mediated tumour sup-
pressive mechanisms in its downstream signaling. The loss 
of p53 protein turning off the activity of p53 networks, 
and resulted in suppression of cell cycle arrest genes (p21, 
GADD45A and 14-3-3σ), apoptosis genes (Bax, PUMA, 
Noxa and Bid) and senescence (p21) (Sax et  al. 2002; 
Herrero et  al. 2016). Loss of p53 function also promotes 
angiogenesis (TSP1 and maspin) (Herrero et  al. 2016). 
Besides that, p53 disruption also affects cell metabolism, 
autophagy, necrosis, anti-oxidant defense and microRNA 
expression (Hager and Gu 2014; Liu et  al. 2014). Alto-
gether, they facilitate the proliferation and pro-longed sur-
vival of MM cells. The miR-125b, miR-194 and miR-215 
are potential therapeutic targets in MM, which are related 
to p53 pathway (Pichiorri et al. 2010). These miRNAs are 
transcriptionally activated by p53 and able to form positive 
feedback loop with p53 to help to activate the gene under 
stress condition (Bi and Chng 2014). The miR-125b, miR-
194 and miR-215 also capable of inhibit cancer cell pro-
liferation through promoting the p53-mediated apoptosis, 
cell cycle arrest and senescence (Zhang et al. 2015). These 
miRNAs are commonly down-regulated in MM (Pichiorri 
et  al. 2010). However, instead of under-expressed, they 
Fig. 1  Verification of miRNA expression by RT-qPCR. The miR-
150-5p and miR-4430 were down-regulated and up-regulated, respec-
tively in MM compared to the controls. Importantly, the fold changes 
cannot directly compared between assays due to differences in calcu-
lation methods, but the general trend of up-regulation and down-regu-
lation can be compared. Error bars represent the standard deviation of 
the mean (SD). *p < 0.001; **p < 0.05
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were over-expressed in this study. This could be explained 
by the complexity of regulations and functions of miRNAs 
in cancers. Research found that a single miRNA can act 
as oncomir or tumour suppressor simultaneously (Li et al. 
2012). For example, miR-196b can target either tumour 
suppressor, FAS or oncogene, HOXA9/MEIS1 in leukae-
mia (Li et al. 2012). When miR-196b was over-expressed in 
leukaemia cells, it represses the function of FAS and at the 
same time promotes cell proliferation and inhibits apopto-
sis via increases expression of HOXA9/MEIS1. Apart from 
that, miRNAs regulate gene expression at the post-tran-
scriptional level and at the same time their expression are 
regulated by transcription factors (Wang et al. 2010). More-
over, other studied showed that the expression of miRNAs 
is not only regulated at transcriptional level but also at the 
post-transcriptional level during the downstream processing 
stages (Siomi and Siomi 2010). All of these findings imply 
that the expression of the miRNA in oncogenesis is varied 
depending on the potential influences of the different bio-
logical and cellular contexts (Nam et al. 2014).
miRNA-target prediction
The miRNA-mRNA enrichment analysis revealed that 
CCNA2, CYSLTR2, RASGRF2 and HKDC1 were targeted 
by more than one miRNAs (except for RAD54L) (Table 1). 
Out of 15 putative miRNAs identified in this study, only a 
few of them are concomitant with cancers. They are miR-
150, miR-125b, miR-33a, miR-9 and miR-211. Interest-
ingly, miR-150 and miR-125b are closely related to B 
cell differentiation and therefore highlighted their criti-
cal roles in myelomagenesis. The c-Myb, Mucin 4, TAMs 
Table 2  Aberrant miRNAs and their function, target and clinical relevance in oncogenesis
miRNA Fold change Function/target/clinical relevance
miR-125b 21.9 Association with B cell maturation Malumbres et al. (2009)
High expression resulted in down-regulation of IRF4 and Blimp1 Gururajan et al. (2010)
Reduction of cell death in dexamethasone induced MM Murray et al. (2013)
Transcriptional target of p53 Pichiorri et al. (2010), Huang et al. (2012) and Zhang et al. (2015)
miR-148a 19.2 Up-regulation in plasma cells of MM and association with shorter progression free survival Huang et al. (2012)
miR-196b 12.5 Down-regulation increased CCND2 expression and induced cell cycle at G1 to S phase Saki et al. (2014)
miR-21 10.9 Induction by IL-6/STAT3 pathway upon adherence of bone marrow cells and bone marrow stromal cells Löffler et al. 
(2007)
Over-expression inhibited apoptosis and increased drug resistance Wang et al. (2011)
Association with early pathogenesis of MM Pichiorri et al. (2008)
miR-20a 9.2 Up-regulation by c-MYC over-expression Zhou et al. (2010)
Aberration was associated with down-regulation of pro-apoptotic genes, BIM and SOC-1 Anderson and Carrasco 
(2011)
Up-regulation in plasma cells of MM and correlation with shorter progression free survival Chen et al. (2011) and 




8.4 Inhibition in cell migration and invasion by targeting
IGF1 and IGF1R
Direct transcriptional target of p53 Pichiorri et al. (2010) and Zhang et al. (2015)
Down-regulation was associated with promoter hypermethylation, which would impair the p53/MDM2 loop and 
promotion of MM development Pichiorri et al. (2010)
miR-330-3p 7.9 Over-expression in aggressive MM and association with shorter overall survival rate Lionetti et al. (2013)
miR-214 7.9 Down-regulation was caused by DNA methylation and resulted in inhibition of myeloma cell proliferation Gutiérrez 
et al. (2010)
Target PSMD10 and ASF1B Saki et al. (2014)
miR-150-5p −3.5 Control B cell differentiation by targeting c-Myb Xiao et al. (2007) and Fernando et al. (2012)
Promote cell growth, invasion and metastasis via interaction with Mucin 4 Grammatikakis et al. (2013)
Potential target of survivin Undi et al. (2013)
Target tumour associated macrophages (TAMs) to induce VEGF production and tumour growth via angiogenesis Liu 
et al. (2013)
Potential therapeutic target in MM Palagani et al. (2014)
miR-361-3p −4.3 Association with t(11;14) translocation
Target PPP2R4, the activation of IL-6 signaling and resulted in increased cell growth and survival Lionetti et al. 
(2009)
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and survivin/BIRC5 are a few potential targets of miR-150 
(Xiao et  al. 2007; Fernando et  al. 2012; Grammatikakis 
et al. 2013; Liu et al. 2013; Undi et al. 2013). So far, there 
is no evidence showing the biological relationship between 
miR-150 and RAD54L or CCNA2. For the first time, our 
findings exhibited the possible roles of miR-150 in regulat-
ing two important cell cycle associated genes, RAD54L and 
CCNA2. The RAD54L is involved in DNA double strand 
break repair and chromatin remodeling in G1/ S-transition 
via homologous recombination (Mjelle et  al. 2015). Its 
misrepaired would cause various mutations, deletions and 
oncogenic translocations in human cells (Agarwal et  al. 
2011; Mjelle et al. 2015). Elevated expression of RAD54L 
was identified in colon and breast cancer, lymphoma and 
meningioma (Leone et al. 2003). We revealed for the first 
time that RAD54L was over-expressed in MM and its aber-
rant expression might be caused by down-regulation of 
miR-150. Another putative target of miR-150, the CCNA2 
gene is a well-established cell cycle control gene, which is 
a genetic marker for prognostic and outcome prediction in 
MM and other cancers (García-Escudero et al. 2010).
Aberrant expression of miR-125b was implicated in vari-
ous cancers such as colon, prostate, and lymphoma (Jacinto 
et al. 2007; Mahapatra et al. 2012). The IRF4, Blimp1 and 
p53 were identified as its possible targets (Table  2). Our 
integrative analysis of miRNA-mRNA expression data 
predicted new potential targets of miR-125b, namely RAS-
GRF2 and CYSLTR2. Low expression of RASGRF2 has 
been described in lymphoma, lung cancer, cancer cell lines 
and primary tumour but not in MM (Chen et al. 2006). The 
RASGRF2 is a RAS signaling protein involved in regulat-
ing conversion of active or inactive forms of RAS protein 
(Chen et al. 2006). RAS protein is an important component 
in signal transduction pathway as it activates intracellular 
pathways that affect the biological processes related to cell 
proliferation, survival, and motility (Agarwal et al. 2011). 
We suggests that disruption of normal signaling pathways 
through under-expression of RASGRF2 might facilitate 
cancerous cell growth and invasion. Besides RASGRF2, 
CYSLTR2 is another potential target of miR-125b identified 
in this study. The role of CYSLTR2 in myelomagenesis is 
still unknown although its dysregulation has been shown to 
facilitate cell proliferation and migration of colon cancer 
cells via CysLT signaling (Bengtsson et al. 2013).
Other potential miRNAs such as dysregulation of miR-
33a, miR-9 and miR-211 have never been reported in asso-
ciation with MM transformation and disease progression. 
However, they have been shown to play crucial roles in 
other cancers such as breast, ovarian, melanoma, and glio-
blastoma (Ibrahim et al. 2011; Blandino et al. 2012; Wang 
et al. 2013; Xia et al. 2015).
This study has limitation due to the used of small sam-
ple size. In addition, CD138+ plasma cells enrichment was 
not performed due to the limited capacity of bone mar-
row samples received from the patients. Our future study 
aims to confirm the microarray findings with larger sam-
ple size, possibly with CD138+ purified plasma cells from 
the patients. Besides that, the miRNA-targets identified 
in this study is predicted based on the integrative analysis 
of miRNA and mRNA expression profiles of the matched 
samples, the biological relevance of the miRNA-targets 
need to be further verified by using dual-luciferase reporter 
assay system.
Conclusions
Our present study revealed potential miRNAs and miRNA-
target underlying the molecular pathogenesis of MM. One 
of the most significant findings are the identification of new 
possible targets for two B cell related miRNAs, miR-150 
and miR-125b. Our findings predicted that miR-150 might 
be negative regulator for two critical cell cycle control 
genes, RAD54L and CCNA2, whereas miR-125b poten-
tially target RAS and CysLT signaling proteins, namely 
RASGRF2 and CYSLTR2. The miRNA and miRNA-tar-
get identified in this study might be important therapeutic 
markers in MM, which is worthy for further investigation.
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